Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To evaluate the safety, tolerability and efficacy of elagolix (ABT-620), administered once daily (QD) or twice daily (BID) for 3 months in the management of moderate to severe endometriosis-associated pain, and to evaluate the effect of elagolix treatment on analgesic use for endometriosis-associated pain.
Inclusion criteria
- Moderate to Severe Endometriosis Associated Pain